Share

Back to Search Results

mAbs and vaccines against SARS CoV-2

Project Number
1ZIAAI005145-01

Contact PI/Project Leader
SULLIVAN, NANCY J

Awardee Organization
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

Description

Abstract Text

A **vaccine** against SARS CoV 2 virus would be highly significant in preventing outbreaks which are known to occur naturally. SARS CoV 2 is the strain of coronavirus that causes coronavirus disease 2019 (**COVID**-19), the respiratory illness responsible for the **COVID**-19 pandemic for which there is no effective treatment or cure. Therefore, **vaccine** studies are critically important for protection against infection. We developed a highly effective **vaccine** strategy and antibody identification strategy for Ebola virus infection in non-human primates. Our laboratory has demonstrated that protective immunity to Ebola can be generated with a single inoculation of an adenoviral vector **vaccine**, a result with significant implications for conducting enhanced ring vaccination during an Ebola outbreak. We aim to use a similar strategy for SARS CoV2.

Public Health Relevance Statement

Data not available.

NIH Spending Category

Biotechnology Coronaviruses Emerging Infectious Diseases Immunization Infectious Diseases Orphan Drug Prevention Rare Diseases Vaccine Related

Project Terms

2019-nCoV Adenovirus Vector Antibodies **COVID**-19 **COVID**-19 pandemic Coronavirus Disease Outbreaks Ebola Ebola virus Immunity Infection Laboratories Monoclonal Antibodies Therapeutic Vaccination Vaccines Virus Virus Diseases effective therapy nonhuman primate prevent respiratory **vaccine** trial vector **vaccine**

Details

Contact PI/ Project Leader

Name
SULLIVAN, NANCY J

Other PIs

Not Applicable

Program Official

Name

Contact
Email not available

Thank you for your feedback!

Title

Contact
Email not available

Organization

Name
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

City

Country

Department Type
Unavailable

Organization Type
Unavailable

State Code

Congressional District

Other Information

FOA

Study Section

Fiscal Year
2020

Award Notice Date

Administering Institutes or Centers
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

DUNS Number CFDA Code

Project Start Date

Project End Date

Budget Start Date

Budget End Date

Project Funding Information for 2020

Total Funding
$1,113,300

Direct Costs
$0

Indirect Costs
$0

Year	Funding IC	
2020	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES	$1,113,300

NIH Categorical Spending

Click here for more information on NIH Categorical Spending

Funding IC	FY Total Cost by IC	NIH Spending Category
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES	$1,113,300	Biotechnology; Coronaviruses; Emerging Infectious Diseases; Immunization; Infectious Diseases; Orphan Drug; Prevention; Rare Diseases; Vaccine Related;

Sub Projects

No Sub Projects information available for 1ZIAAI005145-01

Publications

Export

Journal (Link to PubMed abstract)	Authors	Publication	Similar

Thank you for your feedback!

Publication (Link to PubMed abstract)	Authors	Publication Year	Similar Publications	Citedby	Note
Protective antibodies elicited by SARS-CoV-2 spike protein vaccination are boosted in the l after challenge in nonhuman primates.					
Science translational medicine 2021 08 18; 13 (607)	Francica, Joseph R; Flynn, Barbara J;	2021			
View All					
mRNA-1273 protects against SARS-CoV-2 beta infection in nonhuman primates.					
Nature immunology 2021 10; 22 (10) 1306-1315	Corbett, Kizzmekia S; Werner, Anne P;	2021			
View All					
COVID-19 vaccine mRNA-1273 elicits a protective immune profile in mice that is not assoc with vaccine-enhanced disease upon SARS-CoV-2 challenge.					
Immunity 2021 08 10; 54 (8) 1869-1882.e6	DiPiazza, Anthony T; Leist, Sarah R;	2021			
View All					
Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants.					
Science (New York, N.Y.) 2021 Aug 13; 373 (6556)	Wang, Lingshu; Zhou, Tongqing;	2021			iCite
View All					
Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine.					
The New England journal of medicine 2021 04 15; 384 (15) 1468-1470	Wu, Kai; Werner, Anne P; Koch,	2021			iCite
View All					
High-throughput, single-copy sequencing reveals SARS-CoV-2 spike variants coincident wi mounting humoral immunity during acute COVID-19.					
PLoS pathogens 2021 04; 17 (4) e1009431	Ko, Sung Hee; Bayat Mokhtari,	2021			iCite
View All					
Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates.					
The New England journal of medicine 2020 10 15; 383 (16)	Corbett, Kizzmekia S; Flynn, Barbara;	2020			iCite

Patents

No Patents information available for 1ZIAAI005145-01

Outcomes

The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.

No Outcomes available for 1ZIAAI005145-01

Clinical Studies

No Clinical Studies information available for 1ZIAAI005145-01

Thank you for your feedback!

News and More

Related News Releases

No news release information available for 1ZIAAI005145-01

History

No Historical information available for 1ZIAAI005145-01

Similar Projects

No Similar Projects information available for 1ZIAAI005145-01

Thank you for your feedback!